ijms-logo

Journal Browser

Journal Browser

Special Issue "Secondary Metabolites as Therapeutics of Human Pathogens"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: 30 November 2021.

Special Issue Editor

Dr. Wieslaw Swietnicki
E-Mail Website
Guest Editor
Institute of Immunology and Experimental Therapy of the PAS, Dept. of Immunology of Infectious Diseases, 53-114 Wroclaw, Ul. Weigla 12, Poland
Interests: virulence systems; type III secretion system; Yersinia pestis; Pseudomonas aeruginosa; EPEC; inhibitors; vaccines
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Secondary metabolites are compounds produced by organisms for the purpose of signal transduction, the blockage of specific pathways or simply for killing other organisms. The molecules range in size from a few hundred to as much as a few thousand Daltons and are frequently made with the help of non-ribosomal protein synthesis machinery on operons encoding other components, including transport systems, antitoxin components, and gene expression regulators. Secreted components have been used frequently as antibiotics, directly or after synthetic modifications.

This Special Issue will consider manuscripts describing work concentrated in the following areas:

  1. Non-ribosomal protein synthesis proteins: identification, mechanisms of action, structural studies and biological activity against human pathogens;
  2. Experimental identification of compounds with biological activity against human pathogens;
  3. Computational approaches to identifying compounds and predicting their structures;
  4. Genomic regulation of operons producing secondary metabolites and their distribution in other organisms;
  5. Animal models describing the use of secondary metabolites in the therapy of diseases caused by human pathogens;
  6. ADME/toxicology studies and chemical modification of secondary metabolites to improve their application as potential therapeutics.

Dr. Wieslaw Swietnicki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Functional Insights into Silymarin as an Antiviral Agent against Enterovirus A71 (EV-A71)
Int. J. Mol. Sci. 2021, 22(16), 8757; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168757 - 15 Aug 2021
Viewed by 510
Abstract
Enterovirus A71 (EV-A71) is a major neurovirulent agent capable of causing severe hand, foot and mouth disease (HFMD) associated with neurological complications and death. Currently, no FDA-approved antiviral is available for the treatment of EV-A71 infections. The flavonoid silymarin was shown to exert [...] Read more.
Enterovirus A71 (EV-A71) is a major neurovirulent agent capable of causing severe hand, foot and mouth disease (HFMD) associated with neurological complications and death. Currently, no FDA-approved antiviral is available for the treatment of EV-A71 infections. The flavonoid silymarin was shown to exert virucidal effects, but the binding site on the capsid was unknown. In this study, the ligand interacting site of silymarin was determined in silico and validated in vitro. Moreover, the potential of EV-A71 to develop resistance against silymarin was further evaluated. Molecular docking of silymarin with the capsid of EV-A71 indicated that silymarin binds to viral protein 1 (VP1) of EV-A71, specifically at the GH loop of VP1. The in vitro binding of silymarin with VP1 of EV-A71 was validated using recombinant VP1 through ELISA competitive binding assay. Continuous passaging of EV-A71 in the presence of silymarin resulted in the emergence of a mutant carrying a substitution of isoleucine by threonine (I97T) at position 97 of the BC loop of EV-A71. The mutation was speculated to overcome the inhibitory effects of silymarin. This study provides functional insights into the underlying mechanism of EV-A71 inhibition by silymarin, but warrants further in vivo evaluation before being developed as a potential therapeutic agent. Full article
(This article belongs to the Special Issue Secondary Metabolites as Therapeutics of Human Pathogens)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Actinomycetal secondary metabolites as quorum sensing inhibitors targeting agr type systems of pathogens: in vitro and in silico study
Back to TopTop